Zentalis Pharmaceuticals 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
to this next fireside chat with Zentalis. My name is Michael Schmidt, and I am pleased to welcome Julie Eastland, CEO of Zentalis. Julie, welcome. Thanks for joining us.
Thank you, as always. Appreciate the invite to the conference.
Maybe for those who are just getting to know Zentalis, Julie, what is the core idea behind the company, azenosertib, and why is Cyclin E1-positive ovarian cancer the right place to start with this asset?
Those are excellent questions. I first, before I begin, just want to make note that there is likely going to be questions that will require some forward-looking statements, including some estimates and projections, and we advise folks to review our filings with the SEC for risk factors associated with those. We did just report earnings and a corporate update today, so we can certainly talk about some of those things as a backdrop, of course. Zentalis is focused on developing meaningful new therapies for oncology indications, and our lead program, and our main program is azenosertib. azenosertib is a small molecule WEE1 inhibitor. Its focus in Cyclin E1 ovarian cancer has really been derived from a vast body of data of studying azenosertib in the clinical setting across different studies in the ovarian cancer setting.
That is, as a dose escalation study that was first designed to understand dose and schedule, and then in addition to that, combination trials and single-agent trials in ovarian. What we've found as we've looked back to understand patient populations that we believe would benefit most in ovarian cancer, we have identified a group of patients that are defined as Cyclin E1-positive patients. That definition is patients who have Cyclin E1 protein expressions at levels that meet a bar where we see a high correlation of response to that protein expression. Importantly, I think we are working to help folks understand that protein expression differs from gene amplification, and that is that protein expression is both the result of gene amplification and other factors, and is broader than whether or not your gene is amplified for CCNE1.
Importantly, we believe all patients should be screened, because even those patients without amplification can have high Cyclin E1 protein expression and could potentially benefit from azenosertib.
I think the percentage is 50% of patients in ovarian cancer.
Is that correct? Yeah. In our historical studies, as well as looking back at real-world data, we estimate that approximately 50% of the PROC patients express Cyclin E1 levels that would meet our cutoff based on our IHC assay.
Okay. And so we've seen the phase I-B, I guess, or phase II data a few times now in recent history, but the most recent update was really at ESMO here just a couple weeks ago. And so just remind us what the data showed and what it means for the program.
Yeah. It's exciting data. So DENALI is a phase II study. It had multiple parts. Part I-B read out initially in 2025, and the data at ESMO updated that and included new data around the overall survival of those patients. Importantly, this overall survival data of Cyclin E1 high expressors was in the range of almost 16 months of additional overall survival for that population, as compared to Cyclin E1 negative patients, which had about 7.5 months of OS. This really not only strengthens the overall profile of the agent, but also helps to really, again, define and complement the selection of Cyclin E1 high positive patients in this population as a group of patients that could benefit from azenosertib. We did update the ORR slightly.
There was one additional patient that had a response post the previous cutoff, so that response rate of response of valuable patients went up to 37%. And then we updated the duration of response as it matured. That is at 5.5 months, and certainly within the range and the bar in which we think is meaningful for these patients that have a tendency to do worse and progress more quickly.
Right. And remind us, that's at the recommended phase II or phase III dose, I guess, correct?
Yeah, that's a really good point. In DENALI part I-B, all patients were dosed at 400 milligrams. That's on a schedule of five days on and two days off. That is the dose that was also selected in part two of this trial that looked at a dose comparison of 300 and 400.
Okay. Yes. How did tolerability look?
I know it was a topic of discussion in the past.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
